Back to today’s briefing

Story perspectives

Study Confirms Biosimilars Match Colorectal Cancer Treatment Efficacy

6/10/2025

42 4

Summary

Story summary

A groundbreaking study in India examined 944 patients battling metastatic colorectal cancer, revealing that treatment with bevacizumab and its biosimilars yielded nearly identical outcomes. With median progression-free survival at 10 months for the original drug and 9.3 months for biosimilars, this research bolsters oncologists' trust in these alternatives, paving the way for broader use in cancer care.

1 of 1

Story summary

A groundbreaking study in India examined 944 patients battling metastatic colorectal cancer, revealing that treatment with bevacizumab and its biosimilars yielded nearly identical outcomes. With median progression-free survival at 10 months for the original drug and 9.3 months for biosimilars, this research bolsters oncologists' trust in these alternatives, paving the way for broader use in cancer care.